Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Collegium Pharmaceutical Inc COLL

Healthcare Biotechnology
Collegium Pharmaceutical, Inc. is a diversified specialty pharmaceutical company. The Company commercializes its pain portfolio, consisting of Xtampza extended-release (ER), Nucynta ER and Nucynta immediate-release (IR), Belbuca, and Symproic in the United States. Xtampza ER is an abuse-deterrent, extended-release, oral formulation of oxycodone. Xtampza ER is a pain treatment option designed... see more

Recent & Breaking News (NDAQ:COLL)

Collegium Announces Fourth Quarter and Full Year 2022 Preliminary Financial Results

GlobeNewswire February 6, 2023

Collegium Provides 2023 Financial Guidance

GlobeNewswire January 4, 2023

Appeals Court Affirms Validity of Collegium's Belbuca® Patents

GlobeNewswire December 22, 2022

Collegium to Participate in Piper Sandler 34th Annual Healthcare Conference

GlobeNewswire November 22, 2022

Collegium Reports Third Quarter 2022 Financial Results

GlobeNewswire November 3, 2022

Collegium to Report Third Quarter 2022 Financial Results on November 3, 2022

GlobeNewswire October 20, 2022

Collegium Announces 11 Poster Presentations at PAINWeek 2022 National Conference

GlobeNewswire August 30, 2022

Collegium Reports Second Quarter 2022 Financial Results

GlobeNewswire August 4, 2022

Collegium to Report Second Quarter 2022 Financial Results on August 4, 2022

GlobeNewswire July 21, 2022

Collegium to Participate in H.C. Wainwright Global Investment Conference

GlobeNewswire May 17, 2022

Collegium Reports First Quarter 2022 Financial Results

GlobeNewswire May 10, 2022

Collegium to Host Conference Call to Discuss First Quarter 2022 Financial Results

GlobeNewswire April 26, 2022

Collegium to Participate in Upcoming Needham Healthcare Conference

GlobeNewswire April 7, 2022

Collegium Appoints Neil McFarlane to its Board of Directors

GlobeNewswire April 6, 2022

Collegium Provides 2022 Financial Guidance

GlobeNewswire April 5, 2022

Collegium Announces Master Settlement Agreement Resolving Pending Opioid-Related Litigation

GlobeNewswire March 30, 2022

Collegium Completes the Acquisition of BDSI

GlobeNewswire March 22, 2022

Collegium Reports Fourth Quarter and Full-Year 2021 Financial Results

GlobeNewswire February 24, 2022

BIODELIVERY SCIENCES INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of BioDelivery Sciences International, Inc. - BDSI

PR Newswire February 16, 2022

SHAREHOLDER ALERT: WeissLaw LLP Investigates BioDelivery Sciences International, Inc.

PR Newswire February 15, 2022